Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06293898 · ClinicalTrials.gov registry record · Phase 1

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

A Phase 1 study of Breast Cancer and Lung Cancer, sponsored by SystImmune.

Recruiting
Registry status
Phase 1
Development phase
280
Enrollment target
17
Study locations

NCT06293898 is a Phase 1 study of Breast Cancer and Lung Cancer that is actively recruiting participants, run by SystImmune. The registered enrollment target is 280 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 17 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06293898, a Phase 1 study of Breast Cancer and Lung Cancer, is actively recruiting participants, sponsored by SystImmune.

RECRUITING
Registry status
Phase 1
Development phase
280 participants
Enrollment target
17
Study locations

Study Summary

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

Conditions Studied

Breast Cancer Lung Cancer Ovarian Cancer Endometrial Cancer Gastric Cancer Cervical Cancer Esophageal Cancer Urothelial Carcinoma Biliary Tract Cancer Gastroesophageal-junction Cancer

Interventions

  • DRUG BL-M07D1

Study Locations (17)

California

  • City of Hope - Duarte
  • Cedars Sinai - Los Angeles
  • Scripps Health - San Diego

Florida

  • University of Miami - Miami
  • Sarah Cannon Research institute - Lake Nona Florida - Orlando

Illinois

  • University of Illinois Cancer Center - Chicago
  • University of Chicago Medicine - Chicago

New York

  • NYU Langone Hospital - Long Island Investigational Pharmacy - Mineola
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York

Alabama

  • University of Alabama Birmingham - Birmingham

Georgia

  • Georgia Cancer Center at Augusta University - Augusta

Massachusetts

  • Dana Farber Cancer Institute - Boston

Michigan

  • Karmanos Cancer Institiute - Detroit

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2024-02-09
Est. Completion 2029-04-15
Phase Phase 1

Sponsor

SystImmune

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06293898

The ClinicalTrials.gov registry entry for NCT06293898 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (90% lower). The listed sponsor is SystImmune, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which BL-M07D1 is the first listed.

NCT06293898 reports 17 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06293898 about?

NCT06293898 is a clinical study titled "Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors". The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

What is the current status of trial NCT06293898?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2024-02-09. Estimated completion is 2029-04-15.

What conditions does trial NCT06293898 study?

This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer.

What interventions are being tested in trial NCT06293898?

The interventions under investigation include: BL-M07D1 (DRUG).

Who is sponsoring clinical trial NCT06293898?

This trial is sponsored by SystImmune, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06293898 being conducted?

This trial has 17 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.